Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMany people notice their relationship with food shifts within the first few weeks of starting Wegovy. Some foods that once felt irresistible taste oddly flat; others seem too rich after a few bites. Yes, food can taste different on Wegovy — and the change is real, though it doesn't affect everyone in the same way or to the same degree. These are prescription-only medicines and a prescriber reviews every case individually, because suitability varies from person to person.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
That moment catches a lot of people off guard. A chocolate bar that used to feel like a treat now tastes overwhelmingly sweet. A takeaway that would have been automatic on a Friday night smells fine but feels unappealing. If you've started Wegovy and found yourself in this situation, you're not imagining it.
Semaglutide (the active ingredient in Wegovy) works primarily as a GLP-1 receptor agonist. GLP-1 is a gut hormone, but its receptors are distributed far more widely than the gut: they're found in the brainstem and the areas involved in reward, motivation and the emotional response to food. When semaglutide activates those pathways, the result isn't just reduced appetite. The brain's readout of how good food feels (its reward value) can change too.
This is sometimes called a reduction in "food reward" or "hedonic eating". A food's flavour compounds haven't changed; what changes is how your brain weights the experience. Rich, fatty or very sweet foods tend to lose their pull most noticeably, possibly because those are the foods that over-activate reward pathways in the first place. Plainer, protein-rich or vegetable-based foods often become easier to eat and even more satisfying, which, from a nutrition standpoint, is a useful shift. If you're curious how that plays out practically, our page on foods that work well during Wegovy treatment covers it in detail.
There's no single experience here. Some people report vivid taste changes from week two onwards; others finish a full titration cycle without noticing much at all. A few find certain foods taste actively unpleasant (metallic, too sweet, or just wrong) while others describe the change more as indifference than disgust.
Several factors likely shape that variation. Individual differences in GLP-1 receptor distribution and sensitivity matter. So does the dose: the perceptual shift tends to be more noticeable at higher maintenance doses than at the 0.25mg starting point, when the medicine is still being introduced gradually by the prescriber. Nausea (which is common in the early weeks, as our guide to Wegovy and food aversion explores) can also blur the picture, making it hard to separate a genuine taste change from a food feeling unappealing simply because your stomach is unsettled.
The NHS medicines page for semaglutide lists nausea, vomiting, diarrhoea and constipation as common side effects; altered taste is not a headline entry in the licensed product information, which means much of what we understand comes from post-marketing reports and patient accounts rather than controlled trial data. That's worth being clear about: the signal is real, but the evidence base is observational rather than the kind of rigorous head-to-head data we have for weight outcomes.
For many people, the change in how food tastes or feels is genuinely useful. If a hyper-palatable, calorie-dense food becomes less compelling, you don't have to white-knuckle your way past it, the pull simply isn't there in the same way. That's part of how Wegovy supports the reduced-calorie approach recommended alongside treatment. The practical eating guidance for people on Wegovy leans into this: prioritising protein and vegetables becomes easier when rich or sweet foods have lost some of their appeal.
There's also an interesting question about food noise (the constant mental chatter about eating, craving and what's in the cupboard) which many people find quiets significantly on semaglutide, and which overlaps with these taste and reward changes.
That said, some changes are worth discussing with your prescriber. If food starts to taste consistently bad rather than just less interesting, if you're struggling to eat enough to stay nourished, or if the aversion extends to foods you need for balanced nutrition, those aren't things to push through alone. Keeping a simple note on your phone about what you're managing to eat comfortably is a practical habit, especially in the titration phase, before a routine check-in. The full picture of how semaglutide affects food perception covers some of the more unusual reports, including changes to coffee and alcohol.
Side effects, including anything unexpected around taste or eating, can be reported to the MHRA via the Yellow Card scheme, that reporting helps build the UK evidence base for medicines like Wegovy over time.
If you're considering treatment and want to understand what to expect, checking your eligibility with our prescribers is the right first step, the consultation is free, and a real clinician reads every submission the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.